60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded at Zacks Research

Zacks Research upgraded shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

Several other equities research analysts have also weighed in on SXTP. Ascendiant Capital Markets lowered their price objective on 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of 60 Degrees Pharmaceuticals in a research note on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (e)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Thursday, November 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.50.

60 Degrees Pharmaceuticals Stock Performance

Shares of SXTP stock opened at $1.01 on Tuesday. The firm has a fifty day moving average of $1.38 and a 200-day moving average of $1.74. The stock has a market cap of $4.27 million, a price-to-earnings ratio of -0.29 and a beta of 2.79. 60 Degrees Pharmaceuticals has a 52-week low of $0.85 and a 52-week high of $12.45.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its earnings results on Thursday, November 13th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.55. The business had revenue of $0.53 million during the quarter, compared to the consensus estimate of $0.38 million. On average, sell-side analysts predict that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.